Dr Long talks to ecancertv at ECC 2015 about the changing landscapes of melanoma treatment with immunotherapy.

She also discusses her research involving talimogene laherparepvec (T-VEC), a herpes simplex virus-1-based intralesional oncolytic immunotherapy that provides durable responses in patients with advanced melanoma.

Specifically, she talks about data from the phase Ib part of the MASTERKEY265 study in which a combination of T-VEC and the PD-1 inhibitor pembrolizumab was used in patients with unresectable stage IIIB to IV melanoma.

ecancer's filming at ECC 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

свернуть